Investigational Drug Information for Xanomeline
✉ Email this page to a colleague
What is the development status for investigational drug Xanomeline?
Xanomeline is an investigational drug.
There have been 10 clinical trials for Xanomeline.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 16th 2020.
The most common disease conditions in clinical trials are Schizophrenia and [disabled in preview]. The leading clinical trial sponsors are Karuna Therapeutics, Karuna Pharmaceuticals, and Zai Lab (Shanghai) Co., Ltd.
There are two hundred and fifty-one US patents protecting this investigational drug and zero international patents.
Summary for Xanomeline
| US Patents | 251 |
| International Patents | 2,601 |
| US Patent Applications | 1,327 |
| WIPO Patent Applications | 633 |
| Japanese Patent Applications | 277 |
| Clinical Trial Progress | Phase 2 (2020-12-16) |
| Vendors | 49 |
Recent Clinical Trials for Xanomeline
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Zai Lab (Shanghai) Co., Ltd. | Phase 3 |
| A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia | Karuna Therapeutics | Phase 3 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia | Karuna Therapeutics | Phase 3 |
Clinical Trial Summary for Xanomeline
Top disease conditions for Xanomeline
Top clinical trial sponsors for Xanomeline
US Patents for Xanomeline
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Xanomeline | ⤷ Subscribe | Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury | Banyan Biomarkers, Inc. (Alachua, FL) The United States of America, as Represented by the Secretary of the Army (Washington, DC) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | Methods of treating acanthamoeba infection using apocynin | UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | Vaccine composition | NITTO DENKO CORPORATION (Osaka, JP) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | Freeze dried drug nanosuspensions | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Subscribe |
| Xanomeline | ⤷ Subscribe | Muscarinic agonists | Heptares Therapeutics Limited (Welwyn Garden, GB) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Xanomeline
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Xanomeline | China | CN105189482 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | European Patent Office | EP2953940 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | Spain | ES2694299 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | Japan | JP2016507548 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | Japan | JP6478923 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | World Intellectual Property Organization (WIPO) | WO2014122474 | 2033-02-07 | ⤷ Subscribe |
| Xanomeline | Australia | AU2009282117 | 2028-08-11 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
